ERBB2 and central nervous system neoplasm: Preliminary results of the phase 1 trial “BrainChild-01” showed that repetitive intracranial infusion of HER-2 CAR-T on a cohort of pediatric and young adult patients with CNS tumors is safe, well tolerated, and able to induce immune response (18).